Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $30

Benzinga · 3d ago
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $22 to $30.